Ho Chi Minh CityVietnam’s first plasma biological products factory started construction in Thu Duc City Hi-Tech Park with a fractional capacity of 600,000 liters of plasma per year.
“Hopefully next year there will be the first batch of similarly produced blood plasma biological products, completely escaping the import situation like before,” Deputy Minister of Health Do Xuan Tuyen said at the groundbreaking ceremony for the construction of the Bivid pharmaceutical manufacturing factory. Part 1, January 6.
According to Mr. Tuyen, this project marks an important milestone, continuing the recent achievements of the Vietnamese pharmaceutical industry. This contributes to reducing dependence on imported pharmaceuticals, moving towards self-reliance in the production and supply of drugs, vaccines and biological products according to the policies of the Government and Ministry of Health.
The demand for plasma and plasma fractionation products for treatment in Vietnam is quite large. Through voluntary blood donation programs, our country has about two million units of blood. Blood is separated into many products, the most used are red blood cells and platelets. The separated plasma is often not used up, and if thrown away, it would be a waste. Developed countries often take advantage of this source, producing products and blood clotting factors to serve some patients who need transfusions.
Because there is no production factory, Vietnam has to spend a large amount of foreign currency every year to import plasma fractionation products for treatment. This causes patients to have to pay high prices for products, as well as increasing the burden on health insurance.
Delegates attended the groundbreaking ceremony for the first plasma production plant in Vietnam, January 6. Image: Thanh Thuy
Mr. Ngo Duc Binh, General Director of Binh Viet Duc Co., Ltd. – the project investor, said that in the past the company was a pioneer in collecting plasma that met European standards at large hospitals, bringing raw products to the market. going abroad for processing and then importing finished products back to treat patients. With this construction investment, the factory will have a capacity of 600,000 liters of plasma per year, not only meeting the treatment needs of 250 million people in the country, but also improving the autonomy of the health system. Vietnam but also aims to export to international markets.
It is expected that the factory will be completed and put into operation in February 2026, on an area of 82,000 m2, applying modern technology and automation. Glatt Company and Exyte Company from Germany – with world-leading experience, participate in cooperation in design and project implementation. Currently, not many places in the world have plasma factories, because this field requires very high technology.